For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Heron Therapeutics Inc (NASDAQ: HRTX) closed the day trading at $1.09 down -3.54% from the previous closing price of $1.13. In other words, the price has decreased by -$3.54 from its previous closing price. On the day, 1.72 million shares were traded. HRTX stock price reached its highest trading level at $1.14 during the session, while it also had its lowest trading level at $1.07.
Ratios:
For a better understanding of HRTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.56. In the meantime, Its Debt-to-Equity ratio is 9.44 whereas as Long-Term Debt/Eq ratio is at 9.39.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on June 09, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $7. On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.CapitalOne initiated its Overweight rating on April 23, 2024, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 08 ’25 when Rubric Capital Management LP bought 2,387,225 shares for $1.50 per share. The transaction valued at 3,580,838 led to the insider holds 29,100,728 shares of the business.
Morgan Adam bought 1,766,546 shares of HRTX for $2,649,819 on Aug 08 ’25. The Director now owns 8,753,290 shares after completing the transaction at $1.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 199865168 and an Enterprise Value of 292683136. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.29 while its Price-to-Book (P/B) ratio in mrq is 28.45. Its current Enterprise Value per Revenue stands at 1.887 whereas that against EBITDA is 74.003.
Stock Price History:
The Beta on a monthly basis for HRTX is 1.34, which has changed by -0.025862098 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $2.68, while it has fallen to a 52-week low of $1.00. The 50-Day Moving Average of the stock is -9.82%, while the 200-Day Moving Average is calculated to be -37.49%.
Shares Statistics:
Over the past 3-months, HRTX traded about 1.71M shares per day on average, while over the past 10 days, HRTX traded about 1950340 shares per day. A total of 183.32M shares are outstanding, with a floating share count of 181.64M. Insiders hold about 0.94% of the company’s shares, while institutions hold 83.72% stake in the company. Shares short for HRTX as of 1763078400 were 36592556 with a Short Ratio of 20.37, compared to 1760486400 on 32896288. Therefore, it implies a Short% of Shares Outstanding of 36592556 and a Short% of Float of 24.700001.
Earnings Estimates
A comprehensive evaluation of Heron Therapeutics Inc (HRTX) is underway, with the input of 1.0 analysts contributing to its current rating. Analysts are recommending an EPS of between -$0.05 and -$0.05 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.05, with 1.0 analysts recommending between -$0.05 and -$0.05.
Revenue Estimates
4 analysts predict $39.83M in revenue for . The current quarter. It ranges from a high estimate of $40.7M to a low estimate of $39.5M. As of . The current estimate, Heron Therapeutics Inc’s year-ago sales were $40.78M
A total of 4 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $155M, while the lowest revenue estimate was $153.8M, resulting in an average revenue estimate of $154.15M. In the same quarter a year ago, actual revenue was $144.28MBased on 4 analysts’ estimates, the company’s revenue will be $172M in the next fiscal year. The high estimate is $174M and the low estimate is $170M.
